Research programme: triptolide derivatives - Pharmagenesis

Drug Profile

Research programme: triptolide derivatives - Pharmagenesis

Alternative Names: WilGraf

Latest Information Update: 20 Oct 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Pharmagenesis
  • Developer Astellas Pharma; Pharmagenesis
  • Class Diterpenes
  • Mechanism of Action Dinoprostone receptor antagonists; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Autoimmune disorders; Skin disorders; Transplant rejection

Most Recent Events

  • 20 Oct 2015 Preclinical development is ongoing in USA
  • 11 Apr 2005 Yamanouchi has merged with Fujisawa to form Astellas Pharma
  • 26 Sep 2002 Pharmagenesis has entered into a research agreement with Fujisawa
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top